Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)

SHE:002873 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	754.66	856.87	953.26	1,087	968.7	750.18
Other Revenue	0.67	0.67	0.73	0.88	1.15	0.76
Revenue	755.34	857.55	953.98	1,088	969.84	750.95
Revenue Growth (YoY)	-9.99%	-10.11%	-12.29%	12.15%	29.15%	-2.90%
Cost of Revenue	215.83	230.72	219.39	247.65	201.16	165.86
Gross Profit	539.51	626.83	734.59	840.02	768.69	585.09
Selling, General & Admin	469.75	513.64	589.02	673.99	606.18	474.39
Research & Development	42.71	40.47	38.13	21.58	20.38	13.3
Other Operating Expenses	13.96	12	10.54	13.17	13.81	11.52
Operating Expenses	523.61	568.72	637.42	709.27	642.1	498.7
Operating Income	15.9	58.11	97.17	130.75	126.58	86.39
Interest Expense	-10.49	-17.57	-11.8	-10.67	-16.6	-5.47
Interest & Investment Income	0.44	0.67	0.92	0.73	1.37	1.42
Currency Exchange Gain (Loss)	-	-	0	-	-	-
Other Non Operating Income (Expenses)	1.72	-0.05	1.92	-5.41	-2.93	-2.23
EBT Excluding Unusual Items	7.57	41.16	88.21	115.39	108.42	80.11
Gain (Loss) on Sale of Investments	-0	0.02	-0.72	-0.4	-	-
Gain (Loss) on Sale of Assets	-1.02	18.9	-	-0.02	-0.1	-
Asset Writedown	-2.92	-0.71	-0.07	-0.12	-0.37	-0.48
Other Unusual Items	5.53	1.38	5	6.48	8.69	4.31
Pretax Income	9.16	60.76	92.42	121.34	116.65	83.94
Income Tax Expense	1.66	8.43	11.55	9.83	16.04	9.84
Earnings From Continuing Operations	7.5	52.32	80.87	111.52	100.61	74.1
Net Income	7.5	52.32	80.87	111.52	100.61	74.1
Net Income to Common	7.5	52.32	80.87	111.52	100.61	74.1
Net Income Growth	-86.14%	-35.30%	-27.48%	10.85%	35.76%	3.75%
Shares Outstanding (Basic)	230	220	232	232	227	225
Shares Outstanding (Diluted)	230	220	245	244	245	241
Shares Change (YoY)	-0.98%	-9.91%	0.41%	-0.41%	1.34%	6.59%
EPS (Basic)	0.03	0.24	0.35	0.48	0.44	0.33
EPS (Diluted)	0.03	0.24	0.33	0.46	0.41	0.31
EPS Growth	-86.01%	-28.18%	-27.78%	11.30%	33.96%	-2.66%
Free Cash Flow	107.99	26.68	-23.92	-53.38	18.61	107.62
Free Cash Flow Per Share	0.47	0.12	-0.10	-0.22	0.08	0.45
Dividend Per Share	0.060	0.100	0.070	0.100	0.086	0.061
Dividend Growth	-45.45%	42.86%	-30.00%	16.69%	40.03%	20.00%
Gross Margin	71.43%	73.10%	77.00%	77.23%	79.26%	77.91%
Operating Margin	2.10%	6.78%	10.19%	12.02%	13.05%	11.50%
Profit Margin	0.99%	6.10%	8.48%	10.25%	10.37%	9.87%
Free Cash Flow Margin	14.30%	3.11%	-2.51%	-4.91%	1.92%	14.33%
EBITDA	54.96	89.14	117.51	155.38	148.33	105.47
EBITDA Margin	7.28%	10.39%	12.32%	14.29%	15.29%	14.04%
D&A For EBITDA	39.06	31.04	20.34	24.64	21.74	19.09
EBIT	15.9	58.11	97.17	130.75	126.58	86.39
EBIT Margin	2.10%	6.78%	10.19%	12.02%	13.05%	11.50%
Effective Tax Rate	18.08%	13.88%	12.49%	8.10%	13.75%	11.72%
Revenue as Reported	755.34	857.55	953.98	1,088	969.84	750.95
Advertising Expenses	-	16.57	43.46	43.15	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.